Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.
about
The Emerging Role of Disturbed CoQ Metabolism in Nonalcoholic Fatty Liver Disease Development and ProgressionMetabolism in HD: still a relevant mechanism?Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in ratsCoenzyme Q(10) supplementation reverses age-related impairments in spatial learning and lowers protein oxidationRedox proteomics in selected neurodegenerative disorders: from its infancy to future applications.Oxidative stress and mitochondrial dysfunction across broad-ranging pathologies: toward mitochondria-targeted clinical strategies.Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10Therapeutic approaches to preventing cell death in Huntington diseaseCurrent experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials.Why are there no proven therapies for genetic mitochondrial diseases?The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeuticsEvidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.Translational research in Huntington's disease: opening up for disease modifying treatmentEndogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.Milestones in huntington disease.Antioxidants in Huntington's disease.Therapy in Huntington's disease: where are we?A review on the role of quinones in renal disorders.Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.Prospects for neuroprotective therapies in prodromal Huntington's disease.Strategies for oral delivery and mitochondrial targeting of CoQ10.A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.Redox Signaling Mediated by Thioredoxin and Glutathione Systems in the Central Nervous System.Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial.Anthraquinones As Pharmacological Tools and Drugs.Three-Year Follow-Up of High-Dose Ubiquinol Supplementation in a Case of Familial Multiple System Atrophy with Compound Heterozygous COQ2 MutationsCoenzyme Q10 Prevents Mitochondrial Dysfunction and Facilitates Pharmacological Activity of Atorvastatin in 6-OHDA Induced Dopaminergic Toxicity in Rats.
P2860
Q26775025-F2973E0B-7A76-4A76-A895-EF71C3DFDEA5Q28394301-F0C16B9E-195C-4580-8412-9DA73BA98874Q28533959-796AE667-2172-4E1E-8274-BA4D2F28A157Q30429476-26B0B7C8-48C9-49EE-9A61-637174A9CE90Q30446460-857896B8-8398-49A2-8276-676A688B66E5Q33625254-F05DD161-1202-4C5F-8290-928B0E4FEB8DQ33970690-64D2339D-F84A-418E-81F6-EE7F8C56853CQ34411338-E41569C1-4311-42B8-8491-A303C48DAB9EQ34685307-B9299A84-CA02-4E6C-970E-C87A88549D3DQ35162928-ABAA9B0A-2E18-43AF-A462-F07DCAF3FB99Q35216140-6BE17FBD-65E7-4F64-A807-FE2DD6ACC080Q35754248-3B64E975-720B-48AE-B369-E5436E9BE511Q35783279-84AE29AA-B91B-423D-A43D-A5633695C82FQ36722683-A9804BEF-6068-48E8-9B43-7E4747A02805Q37580731-D5B23AE0-62ED-43A7-A717-5558ACE47E87Q37882602-C1F03899-916A-463B-87D9-6542D844F1CEQ37964359-82BDAACB-DF6A-46A0-A87C-1B74C8601B2AQ38006434-C947130E-8EA4-474B-854B-78F8067094EFQ38098184-799D9DBE-830A-4CB1-8845-D0FFD4D059D3Q38167681-D3E759E1-DF25-4944-B7AE-AEF0ECD59D85Q38191477-533072D6-D6DB-46C4-B0B9-74DD0F4CB3D3Q38301993-D45DE17A-544C-4799-A154-CB6F437517F8Q38383918-E55F3743-B1B3-489E-8F0B-C1A35944B53DQ38690806-FF0C6D65-4EF6-4A32-9233-B7BBCF0A06CDQ38786018-1C7F330F-4174-40E1-9BA6-3E4D64A4F9F8Q38816745-C11FEA7A-016E-4D4E-AB7D-2CE69E16E408Q42275709-DCA1ECC2-6CB7-4828-A7CD-F7C8E2E24F81Q48335945-F6C34708-F0A9-459D-9015-E9443801FE21
P2860
Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Safety and tolerability of hig ...... disease and healthy subjects.
@ast
Safety and tolerability of hig ...... disease and healthy subjects.
@en
Safety and tolerability of hig ...... disease and healthy subjects.
@en-gb
Safety and tolerability of hig ...... disease and healthy subjects.
@nl
type
label
Safety and tolerability of hig ...... disease and healthy subjects.
@ast
Safety and tolerability of hig ...... disease and healthy subjects.
@en
Safety and tolerability of hig ...... disease and healthy subjects.
@en-gb
Safety and tolerability of hig ...... disease and healthy subjects.
@nl
prefLabel
Safety and tolerability of hig ...... disease and healthy subjects.
@ast
Safety and tolerability of hig ...... disease and healthy subjects.
@en
Safety and tolerability of hig ...... disease and healthy subjects.
@en-gb
Safety and tolerability of hig ...... disease and healthy subjects.
@nl
P2093
P50
P356
P1433
P1476
Safety and tolerability of hig ...... disease and healthy subjects.
@en
P2093
Arthur Watts
Bernard Ravina
Carol Zimmerman
Danna Jennings
Elisabeth A de Blieck
H Christopher Hyson
Huntington Study Group Pre2CARE Investigators
Ira Shoulson
Joseph Weber
Kristyn Newhall
P2860
P304
P356
10.1002/MDS.22408
P407
P577
2010-09-01T00:00:00Z